FDA gives accelerated approval to Genmab and Seagen's cervical cancer drug

Genmab and Seagen have received accelerated approval from the FDA for tisotumab vedotin, used to treat recurring or metastatic cervical cancer.
Photo: Joost Melis / Genmab / PR
Photo: Joost Melis / Genmab / PR
by marketwire, translated by catherine brett

Genmab and its partner Seagen have obtained accelerated approval for tisotumab vedotin, commercial name Tivdak, for the treatment of recurring or metastatic cervical cancer, from the US Food and Drug Administration (FDA).

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading